HE4 Serum Levels in Patients with BRCA1 Gene Mutation Undergoing Prophylactic Surgery as well as in Other Benign and Malignant Gynecological Diseases

Table 2

Average concentrations and comparisons of serum HE4 and CA125 levels between patients with ovarian cancer and the other study groups.

Group	HE4 [pmol/L]; mean/range; median/95% confidence intervals; 95th percentile	CA 125 [mIU/mL]; mean/range; median/95% confidence intervals; 95th percentile	HE4 [pmol/L]; mean/range; median/95% confidence intervals; 95th percentile	CA 125 [mIU/mL]; mean/range; median/95% confidence intervals; 95th percentile	HE4 [pmol/L]; mean/range; median/95% confidence intervals; 95th percentile	CA 125 [mIU/mL]; mean/range; median/95% confidence intervals; 95th percentile
	All patients		Premenopausal patients		Postmenopausal patients
Ovarian cancers	633.76/15–8160	1480/9.12–10000	308.71/15.57–1500	615.58/25.32–4638.8	751.6/15–8160	1049.7/9.12–10000
	319.36/460.9–806.6	409/671.1–1197.3	95.40/162.2–455.2	354/292.5–938.7	499.2/525.5–977.7	432/710.8–1388.6
	1516.5	4203	1500	2096	1655	4459.7
versus BRCA1 mutations	38.78/15–152.7	21.09/2.98–223	35.73/34–51	23.2/2.98–223	48.3/15–152.7	17.21/3–36.3
	38.25/34.1–43.5	15.64/13.2–28.9	44/30–41.4	15.78/11.5–34.8	47.3/37.1–59.6	15.25/13.2–21.3
	77	30.7	72.3	28.2	78.2	30.7
	0.0000	0.0000	0.0000	0.0000	0.0000	0.0000
versus myomas	45.07/15–88.8	27.49/9.3–173.6	44.12/15–87.8	27.49/9.3–173.6	47.3/16.34–88.8	20.18/10.3–60.2
	44.65/41.6–48.5	18.8/16.9–34.4	43/40.2–48	43/16.2–38.8	48.1/39.9–54.7	16/9.7–30.7
	74.9	58.5	67.7	56.5	77.8	60.2
	0.0000	0.0000	0.0000	0.0000	0.0000	0.0000
versus nonneoplastic ovarian cysts	49.85/24.8–90.4	36.75/4.1–377	49.45/24.8–90.4	41.62/4.1–377	51.47/27.50–73.9	16.67/4.54–82.1
	47.45/46.9–52.8	17.15/24.7–48.8	46.75/46.6–52.8	19.9/27–56.2	50.5/45.2–57.8	7.55/6.8–26.5
			78	124	73.9	82.1
	0.0000	0.0000	0.0000	0.0001	0.0000	0.0000
versus diseases	85.5/39–269.8	201/2.4–715.9	85.5/39–269.8	201/2.4–715.9	—	—
	54.3/26.1–144.9	85/5.9–396.1	54.3/11.7–142.5	85/3.7–442
	269.8	715.9
	0.0027	0.0027	0.0902	0.1302	—	—
versus benign epithelial ovarian	52.54/15–191.1	31.08/3.86–186.72	34.58/15–78.2	22.51/8.56–56.40	65.36/15–191.1	36.8/3.86–186.7
	47.27/39.5–65.6	22.2/19.9–42.2	34.8/22.9–46.2	21.4/13.4–31.6	54.55/45.6–85.1	24.8/18.9–54.6
tumors	131.5	64.7	78.2	56.4	131.5	64.7
	0.0000	0.0000	0.0001	0.0000	0.0000	0.0000
versus endometrial cancers	477.53/21.37–13762	134.62/11.6–1200	184.45/39.1–325.8	25.75/28.4–22.2	498.3/21.37–13762	142.7/11.6–1200
	97.3/−56.1–1011.1	26.6/−37.8–306.9	221.55/−264.5–541.6	25.28/7.8–14.6	98.3/−68.5–1065	29/−42.9–328
	1017	1200.3	325.8	22.2	1017	1200.3
	0.0007	0.0001	—	—	0.0643	0.0001
versus other gynecological cancers	65.98/23.16–208.5	37.34/8.2–101.5	54.69/32.9–81.1	41.29/8.2–98.5	75.12/23.16–208.5	33.82/11.1–101.5
	45.9/55.1–76.9	13/19.9–54.8	53.3/47.1–61.6	17.1/7.9–74.6	65.1/56.3–93.9	17.6/10.9–56.7
	145.7	101.5	81.1	98.5	145.7	101.5
	0.0000	0.0000	0.0085	0.0006	0.0000	0.0000
versus endometrial polyps	48.08/15–141.8	21.66/2.6–182.8	41.31/15–81.30	17.16/16.99–29	53/15–141.8	23.35/2.6–182.8
	46.5/43.7–52.5	13.7/5.4–37.9	42/35.9–46.7	18.2/9.3–25.1	51/46.7–59.4	12.5/0.35–46.4
	83.6	34.2	72.1	29	88.9	182.8
	0.0000	0.0000	0.0000	0.0002	0.0000	0.0000
versus other cancers	236.51/12.1–580.1	615.4/21.8–3091	—	—	236.51/15–580.1	615.4/21.8–3091
	209.9/88.2–384.2	257.3/−238.5–1469.3			209.9/49.7–389	257.3/−332.8–1680.8
	580.1	3091			580.1	3091
	0.2790	0.2858	—	—	0.0798	0.2471